SALEM FITSUM: Open Payments
NPI 1861177131 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,465 in 202 payments from 16 companies in 2025. Trend: 2023 $395 · 2024 $2,676 · 2025 $5,465
Food & beverage: $5,465
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 28 | $894 |
| Alkermes, Inc. | 24 | $808 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 27 | $763 |
| ABBVIE INC. | 29 | $757 |
| Neurocrine BioSciences, Inc. | 17 | $513 |
| Vanda Pharmaceuticals Inc. | 11 | $465 |
| E.R. Squibb & Sons, L.L.C. | 20 | $449 |
| Janssen Pharmaceuticals, Inc | 9 | $190 |
| Supernus Pharmaceuticals, Inc. | 13 | $160 |
| Indivior Inc. | 5 | $119 |
Products named: CAPLYTA, VRAYLAR, ARISTADA, REXULTI, INGREZZA, FANAPT, COBENFY, ABILIFY ASIMTUFII.
Industry payments across NV — which companies pay providers there.
